Antigen Express

Generex releases positive interim phase II breast cancer vaccine trial results

Friday, February 14, 2014 01:15 PM

Generex Biotechnology has announced that recent results from a phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011.

More... »

WIRB Copernicus Group

Generex touts positive AE37 cancer vaccine technology

Friday, June 8, 2012 11:56 AM

Generex Biotechnology reported promising technology and clinical results from its on-going phase II trial of the AE37 breast cancer vaccine being developed by its subsidiary Antigen Express.

More... »

CRF Health eCOA webinar series

Generex publishes trial results

Monday, July 11, 2011 12:28 PM

Generex Biotechnology has published studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology.  Antigen Express, Generex’s subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. 

More... »

Generex publishes study results for type I diabetes

Wednesday, May 4, 2011 01:01 PM

Generex Biotechnology has published results of studies applicable to the early diagnosis, and possibly treatment of type I diabetes. The study, entitled "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type I Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism Research. The article reports on the results of a collaborative study between scientists at the University Campus Bio-Medico in Rome, Italy and scientists at Generex's wholly-owned subsidiary, Antigen Express.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs